Pasquale Benedetto, MD
Medical Oncology · Miami, FLNPI 1528095775
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $805 of the $905 with a category attached, or 88.9%. 16 manufacturers reported payments, led by Boehringer Ingelheim at 24.8% of the total. Reporting peaked in 2019 at $359 and has fallen 70.6% since, to $105 in 2025. That places this record below the midpoint for medical oncology clinicians in FL, where the typical reported total is $8,890.
Across 27 payments — averaging $33.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$224
- Astellas Pharma US Inc$143
- Genentech USA, Inc.$125
- Pfizer$61
- Novartis$58
- Daiichi Sankyo Inc.$52
- plus $241 from 10 others
Across 92 payments — averaging $13,261 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exelixis Inc.$1M
- Janssen Research & Development, LLC$103K
- Astellas Pharma Global Development$42K
- E.r. Squibb & Sons, L.L.C.$32K
- AVEO Pharmaceuticals, Inc.$200
What the payments were for
- Food & beverage$80589%
- Education$10011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 2 | $224 |
| Astellas Pharma US Inc | 3 | $143 |
| Genentech USA, Inc. | 1 | $125 |
| Pfizer | 3 | $61 |
| Novartis | 3 | $58 |
| Daiichi Sankyo Inc. | 2 | $52 |
| Bristol Myers Squibb | 3 | $47 |
| Eisai Inc. | 2 | $36 |
| Beone Medicines USA, Inc. | 1 | $33 |
| Sanofi | 1 | $25 |
| Dendreon Pharmaceuticals LLC | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Amgen | 1 | $16 |
| EMD Serono, Inc. | 1 | $16 |
| GSK | 1 | $13 |
| Array Biopharma Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TECENTRIQ$125
How this compares
$905 in reported general payments places this provider in the 15th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 37 | $654,364 |
| Sunitinib Malate | 15 | $65,502 |
| Imatinib Mesylate | 12 | $1,730 |
| Levothyroxine Sodium | 11 | $114 |
| Alprazolam | 12 | $112 |
| Methylprednisolone | 12 | $86 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Miami
- Neil LoveMiami$5.6M
- Sarbajit MukherjeeMiami$232K
- Bruna Pellini FerreiraMiami$158K
- Coral OlazagastiMiami$134K
- Jonathan TrentMiami$102K
- Gilberto LopesMiami$99K
- Craig MoskowitzMiami$94K
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.